GA&HA-Modified Liposomes for Co-Delivery of Aprepitant and Curcumin to Inhibit Drug-Resistance and Metastasis of Hepatocellular Carcinoma

References

• Frager SZ, Schwartz JM. Hepatocellular carcinoma: epidemiology, screening, and assessment of hepatic reserve. Curr Oncol. 2020;27(13):138–143. doi:10.3747/co.27.7181
   Web of Science ®Google Scholar
• Anwanwan D, Singh SK, Singh S, Saikam V, Singh R. Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta Rev Cancer. 2020;1873(1):188314. doi:10.1016/j.bbcan.2019.188314
   PubMed Web of Science ®Google Scholar
• Song MJ. Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma. World J Gastroenterol. 2015;21(13):3843. doi:10.3748/wjg.v21.i13.3843
   PubMed Web of Science ®Google Scholar
• Marengo A, Rosso C, Bugianesi E. Liver cancer: connections with obesity, fatty liver, and cirrhosis. Annu Rev Med. 2016;67(1):103–117. doi:10.1146/annurev-med-090514-013832
   PubMed Web of Science ®Google Scholar
• Williamson T, Sultanpuram N, Sendi H. The role of liver microenvironment in hepatic metastasis. Clin Transl Med. 2019;8(1). doi:10.1186/s40169-019-0237-6
   PubMed Web of Science ®Google Scholar
• Brodt P. Role of the microenvironment in liver metastasis: from pre- to prometastatic niches. Clin Cancer Res. 2016;22(24):5971–5982. doi:10.1158/1078-0432.Ccr-16-0460
   PubMed Web of Science ®Google Scholar
• Gysler SM, Drapkin R. Tumor innervation: peripheral nerves take control of the tumor microenvironment. J Clin Invest. 2021;131(11). doi:10.1172/jci147276
   PubMed Web of Science ®Google Scholar
• Zahalka AH, Frenette PS. Nerves in cancer. Nat Rev Cancer. 2020;20(3):143–157. doi:10.1038/s41568-019-0237-2
   PubMed Web of Science ®Google Scholar
• Rosso M, Muñoz M, Berger M. The role of neurokinin-1 receptor in the microenvironment of inflammation and cancer. Sci World J. 2012;2012:1–21. doi:10.1100/2012/381434
   Web of Science ®Google Scholar
• Nizam E, Köksoy S, Erin N. NK1R antagonist decreases inflammation and metastasis of breast carcinoma cells metastasized to liver but not to brain; phenotype-dependent therapeutic and toxic consequences. Cancer Immunol Immunother. 2020;69(8):1639–1650. doi:10.1007/s00262-020-02574-z
   PubMed Web of Science ®Google Scholar
• Li Z, Wang F, Li Y, et al. Combined anti-hepatocellular carcinoma therapy inhibit drug-resistance and metastasis via targeting “substance P-hepatic stellate cells-hepatocellular carcinoma” axis. Biomaterials. 2021;276:121003. doi:10.1016/j.biomaterials.2021.121003
   PubMed Web of Science ®Google Scholar
• Berger M, Neth O, Ilmer M, et al. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo. J Hepatol. 2014;60(5):985–994. doi:10.1016/j.jhep.2013.12.024
   PubMed Web of Science ®Google Scholar
• Ge C, Huang H, Huang F, et al. Neurokinin-1 receptor is an effective target for treating leukemia by inducing oxidative stress through mitochondrial calcium overload. Proc Nat Acad Sci. 2019;116(39):19635–19645. doi:10.1073/pnas.1908998116
   PubMed Web of Science ®Google Scholar
• Singh PM, Borle A, Rewari V, et al. Aprepitant for postoperative nausea and vomiting: a systematic review and meta-analysis. Postgrad Med J. 2016;92(1084):87–98. doi:10.1136/postgradmedj-2015-133515
   PubMed Web of Science ®Google Scholar
• He A, Alhariri JM, Sweren RJ, Kwatra MM, Kwatra SG. Aprepitant for the treatment of chronic refractory pruritus. Biomed Res Int. 2017;2017:1–6. doi:10.1155/2017/4790810
   Web of Science ®Google Scholar
• Muñoz M, Coveñas R, Esteban F, Redondo M. The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs. J Biosci. 2015;40(2):441–463. doi:10.1007/s12038-015-9530-8
   PubMed Web of Science ®Google Scholar
• Muñoz M, Coveñas R. The neurokinin-1 receptor antagonist aprepitant, a new drug for the treatment of hematological malignancies: focus on acute myeloid leukemia. J Clin Med. 2020;9(6):1659. doi:10.3390/jcm9061659
   PubMed Web of Science ®Google Scholar
• Muñoz M, Rosso M. The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug. Invest New Drugs. 2009;28(2):187–193. doi:10.1007/s10637-009-9218-8
   PubMed Web of Science ®Google Scholar
• Priyadarsini KI. The chemistry of curcumin: from extraction to therapeutic agent. Molecules. 2014;19(12):20091–20112. doi:10.3390/molecules191220091
   PubMed Web of Science ®Google Scholar
• Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4(6):807–818. doi:10.1021/mp700113r
   PubMed Web of Science ®Google Scholar
• Zhang X, Dai F, Chen J, et al. Antitumor effect of curcumin liposome after transcatheter arterial embolization in VX2 rabbits. Cancer Biol Ther. 2019;20(5):642–652. doi:10.1080/15384047.2018.1550567
   PubMed Web of Science ®Google Scholar
• Giordano A, Tommonaro G. Curcumin and cancer. Nutrients. 2019;11(10):2376. doi:10.3390/nu11102376
   PubMed Web of Science ®Google Scholar
• Hanafy NAN, Leporatti S, El-Kemary M. Mucoadhesive curcumin crosslinked carboxy methyl cellulose might increase inhibitory efficiency for liver cancer treatment. Mater Sci Eng C Mater Biol Appl. 2020;116:111119. doi:10.1016/j.msec.2020.111119
   PubMed Web of Science ®Google Scholar
• Hanafy NAN. Optimally designed theranostic system based folic acids and chitosan as a promising mucoadhesive delivery system for encapsulating curcumin LbL nano-template against invasiveness of breast cancer. Int J Biol Macromol. 2021;182:1981–1993. doi:10.1016/j.ijbiomac.2021.05.149
   PubMed Web of Science ®Google Scholar
• Pérez-Herrero E, Fernández-Medarde A. Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm. 2015;93:52–79. doi:10.1016/j.ejpb.2015.03.018
   PubMed Web of Science ®Google Scholar
• Hanafy N, Leporatti S, El-Kemary M. Mucoadhesive hydrogel nanoparticles as smart biomedical drug delivery system. Appl Sci. 2019;9(5):825. doi:10.3390/app9050825
   Google Scholar
• Fan Y, Marioli M, Zhang K. Analytical characterization of liposomes and other lipid nanoparticles for drug delivery. J Pharm Biomed Anal. 2021;192:113642. doi:10.1016/j.jpba.2020.113642
   PubMed Web of Science ®Google Scholar
• Kiaie SH, Mojarad-Jabali S, Khaleseh F, et al. Axial pharmaceutical properties of liposome in cancer therapy: recent advances and perspectives. Int J Pharm. 2020;581:119269. doi:10.1016/j.ijpharm.2020.119269
   PubMed Web of Science ®Google Scholar
• Liu C, Liu X-N, Wang G-L, et al. A dual-mediated liposomal drug delivery system targeting the brain: rational construction, integrity evaluation across the blood–brain barrier, and the transporting mechanism to glioma cells. Int J Nanomedicine. 2017;12:2407–2425. doi:10.2147/ijn.S131367
   PubMed Web of Science ®Google Scholar
• Lakkadwala S, Dos Santos Rodrigues B, Sun C, Singh J. Dual functionalized liposomes for efficient co-delivery of anti-cancer chemotherapeutics for the treatment of glioblastoma. J Control Release. 2019;307:247–260. doi:10.1016/j.jconrel.2019.06.033
   PubMed Web of Science ®Google Scholar
• Jiang H, Li ZP, Tian GX, et al. Liver-targeted liposomes for codelivery of curcumin and combretastatin A4 phosphate: preparation, characterization, and antitumor effects. Int J Nanomedicine. 2019;14:1789–1804. doi:10.2147/ijn.S188971
   PubMed Web of Science ®Google Scholar
• Myojin Y, Hikita H, Sugiyama M, et al. Hepatic stellate cells in hepatocellular carcinoma promote tumor growth via growth differentiation factor 15 production. Gastroenterology. 2021;160(5):1741–1754.e1716. doi:10.1053/j.gastro.2020.12.015
   PubMed Web of Science ®Google Scholar
• Castilho-Fernandes A, de Almeida DC, Fontes AM, et al. Human hepatic stellate cell line (LX-2) exhibits characteristics of bone marrow-derived mesenchymal stem cells. Exp Mol Pathol. 2011;91(3):664–672. doi:10.1016/j.yexmp.2011.09.002
   PubMed Web of Science ®Google Scholar
• Luo J, Zhang P, Zhao T, et al. Golgi apparatus-targeted chondroitin-modified nanomicelles suppress hepatic stellate cell activation for the management of liver fibrosis. ACS nano. 2019;13(4):3910–3923. doi:10.1021/acsnano.8b06924
   PubMed Web of Science ®Google Scholar
• Zhang H. Thin-film hydration followed by extrusion method for liposome preparation. Methods Mol Biol. 2017;1522:17–22. doi:10.1007/978-1-4939-6591-5_2
   PubMedGoogle Scholar
• Baghbani F, Moztarzadeh F. Bypassing multidrug resistant ovarian cancer using ultrasound responsive doxorubicin/curcumin co-deliver alginate nanodroplets. Colloids Surf B Biointerfaces. 2017;153:132–140. doi:10.1016/j.colsurfb.2017.01.051
   PubMed Web of Science ®Google Scholar
• Sun Y, Lu J, Yan D, Shen L, Hu H, Chen D. Cellular uptake mechanism and clearance kinetics of fluorescence-labeled glycyrrhetinic acid and glycyrrhetinic acid-modified liposome in hepatocellular carcinoma cells. Environ Toxicol Pharmacol. 2017;53:46–56. doi:10.1016/j.etap.2017.05.003
   PubMed Web of Science ®Google Scholar
• Sun Y, Li X, Zhang L, et al. Cell permeable NBD peptide-modified liposomes by hyaluronic acid coating for the synergistic targeted therapy of metastatic inflammatory breast cancer. Mol Pharm. 2019;16(3):1140–1155. doi:10.1021/acs.molpharmaceut.8b01123
   PubMed Web of Science ®Google Scholar
• Sauraj VK, Kumar B, Priyadarshi R, et al. Redox responsive xylan-SS-curcumin prodrug nanoparticles for dual drug delivery in cancer therapy. Mater Sci Eng C Mater Biol Appl. 2020;107:110356. doi:10.1016/j.msec.2019.110356
   PubMed Web of Science ®Google Scholar
• Yang Y, Liu X, Ma W, et al. Light-activatable liposomes for repetitive on-demand drug release and immunopotentiation in hypoxic tumor therapy. Biomaterials. 2021;265:120456. doi:10.1016/j.biomaterials.2020.120456
   PubMed Web of Science ®Google Scholar
• Wang H, Ellipilli S, Lee WJ, et al. Multivalent rubber-like RNA nanoparticles for targeted co-delivery of paclitaxel and MiRNA to silence the drug efflux transporter and liver cancer drug resistance. J Control Release. 2021;330:173–184. doi:10.1016/j.jconrel.2020.12.007
   PubMed Web of Science ®Google Scholar
• Erin N, Grahovac J, Brozovic A, Efferth T. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance. Drug Resist Updat. 2020;53:100715. doi:10.1016/j.drup.2020.100715
   PubMed Web of Science ®Google Scholar
• Aponte-López A, Muñoz-Cruz S. Mast cells in the tumor microenvironment. Adv Exp Med Biol. 2020;1273:159–173. doi:10.1007/978-3-030-49270-0_9
   PubMed Web of Science ®Google Scholar
• Qiu N, Liu Y, Liu Q, et al. Celastrol nanoemulsion induces immunogenicity and downregulates PD-L1 to boost abscopal effect in melanoma therapy. Biomaterials. 2021;269:120604. doi:10.1016/j.biomaterials.2020.120604
   PubMed Web of Science ®Google Scholar
• Kubo N, Araki K, Kuwano H, Shirabe K. Cancer-associated fibroblasts in hepatocellular carcinoma. World J Gastroenterol. 2016;22(30):6841. doi:10.3748/wjg.v22.i30.6841
   PubMed Web of Science ®Google Scholar
• Wan Y, Meng F, Wu N, et al. Substance P increases liver fibrosis by differential changes in senescence of cholangiocytes and hepatic stellate cells. Hepatology. 2017;66(2):528–541. doi:10.1002/hep.29138
   PubMed Web of Science ®Google Scholar
• Grässel S, Muschter D. Peripheral nerve fibers and their neurotransmitters in osteoarthritis pathology. Int J Mol Sci. 2017;18(5):931. doi:10.3390/ijms18050931
   PubMed Web of Science ®Google Scholar
• Roma-Rodrigues C, Mendes R, Baptista PV, Fernandes AR. Targeting tumor microenvironment for cancer therapy. Int J Mol Sci. 2019;20(4):840. doi:10.3390/ijms20040840
   PubMed Web of Science ®Google Scholar
• Sakai M, Yoshimura R. Mechanotransduction-targeting drugs attenuate stiffness-induced hepatic stellate cell activation in vitro. Biol Pharm Bull. 2021;44(3):416–421. doi:10.1248/bpb.b20-00815
   PubMed Web of Science ®Google Scholar
• Musetti S, Huang L. Nanoparticle-mediated remodeling of the tumor microenvironment to enhance immunotherapy. ACS nano. 2018;12(12):11740–11755. doi:10.1021/acsnano.8b05893
   PubMed Web of Science ®Google Scholar
• Liu M, Song W, Huang L. Drug delivery systems targeting tumor-associated fibroblasts for cancer immunotherapy. Cancer Lett. 2019;448:31–39. doi:10.1016/j.canlet.2019.01.032
   PubMed Web of Science ®Google Scholar
• Sun W, Fu S, Wu S, Tu R. Growing evidence of exosomal MicroRNA-related metastasis of hepatocellular carcinoma. Biomed Res Int. 2020;2020:4501454. doi:10.1155/2020/4501454
   PubMed Web of Science ®Google Scholar